The Latest Breaking News from Alzheimer Disease

3 Stocks to Own as Alzheimer's Drugs Bring Relief

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

StockNews.com · Jun 27, 2023

Are you at risk of developing Alzheimer's Disease? A simple screener can tell—and so can these 11 early warning signs

A quick test that mimics real-life phone tasks can tell if a senior is at risk for Alzheimer’s disease, according to a new study.

Fortune · Jun 23, 2023

LOCALIZE IT: From birth to death, Black Americans struggle with health care system

EDITORS/NEWS DIRECTORS:

The Independent UK · May 23, 2023

Researchers identify rare genetic resilience to Alzheimer’s disease – study

Researchers suggest the findings could open a door for the prevention and treatment of incurable diseases.

The Independent UK · May 15, 2023

Study reveals traffic-related air pollution affects brain function

According to a study from the University of California, Irvine, exposure to traffic-related air pollution causes memory loss, cognitive decline, and the activation of brain pathways linked to the onset of Alzheimer's disease. Read further on Dynamite News:

Dynamite News · May 14, 2023

All you need to know about 'promising' new Alzheimer's drug

Donanemab was shown in a late-stage trial to slow cognitive decline more than a third

Wales Online · May 11, 2023

New Alzheimer’s drug: what you need to know about donanemab’s promising trial results

American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35%. While these results do sound promising, the full data…

The Conversation · May 9, 2023

World ‘on cusp of first generation of treatments for Alzheimer’s’

Almost half of those on donanemab had no clinical progression of disease at one year compared with 29% on a placebo, a study showed.

Evening Standard · May 3, 2023

World ‘on the cusp of first generation of treatments for Alzheimer’s’

THE world is “on the cusp of a first generation of treatments for Alzheimer’s disease”, experts have said, as a new drug was found to slow…

The National (Scotland) · May 3, 2023

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug ‘slows symptoms’

New drug donanemab appears to slow decline associated with Alzheimer’s

The Independent UK · May 3, 2023